Trial Profile

Phase IIa trial of BGB 324 in patients with chronic myeloid leukaemia

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 23 Dec 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bemcentinib (Primary)
Indications Chronic myeloid leukaemia
Focus Therapeutic Use
Sponsors BerGenBio

Most Recent Events

23 Dec 2014 This phase IIa trial in patients with CML is being planned, according to the BerGenBio pipeline.
23 Dec 2014 New trial record
15 Dec 2014 This trial is expected to start in 2015, according to a BerGenBio media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com